Month: March 2024

Roche and Alnylam Report Positive Topline Results from Phase II KARDIA-2 Study


Excerpt from the Press Release: Roche and Alnylam recently announced that the Phase II KARDIA-2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) – the leading cause of cardiovascular disease worldwide – met its primary endpoint. People with mild to moderate hypertension treated with zilebesiran added to a…

Read More

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis


Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Excerpt from the Press Release: BOSTON, March 21, 2024 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham…

Read More

AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion


The deal is the third recent buyout of a radiopharmaceutical developer in recent months, following similar deals from Eli Lilly and Bristol Myers Squibb. Excerpt from the Press Release: AstraZeneca is the latest large pharmaceutical company to make a sizable bet on radiopharmaceutical drugs for cancer, agreeing on Tuesday to acquire longtime biotechnology partner Fusion…

Read More

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer


Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response…

Read More

First Patients Enrolled in Pivotal Study Evaluating HeartBeam’s AIMIGo™ System for Synthesizing a 12-Lead ECG


VALID-ECG Study will Form the Basis of the Company’s Upcoming FDA 510(k) Submission Excerpt from the Press Release: SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has enrolled the first patients in the VALID-ECG (Clinical Validation of…

Read More

Canadian Life Science and Technology Park, Allyant, and IPS-Integrated Project Services, ULC Announce Strategic Partnership for Development of a Life Science, Healthcare, and Technology Park


Excerpt from the Press Release: BLUE BELL, Pa.–(BUSINESS WIRE)–The Canadian Life Science and Technology Park, Allyant, and IPS are proud to announce a strategic, multi-year partnership focused on the advancement of the design and engineering of a state-of-the-art Life Science, Healthcare, and Technology Park. This collaboration brings together expertise in design and construction oversight tailored…

Read More

SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration


New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research Excerpt from the Press Release: BOSTON and ROLLE, Switzerland, March 15, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal…

Read More

Revvity Introduces New Workflow to Accelerate Newborn Sequencing Research


Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs. “This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn…

Read More

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia


Excerpt from the Press Release: REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive…

Read More

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors


– First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) – – Phase 2a portion of Phase 1/2a clinical trial will evaluate IMM-1-104 as monotherapy in PDAC, non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC – – Topline data…

Read More